论文部分内容阅读
近20年来,从微生物次级代谢产物中系统筛选特异的小分子酶抑制剂的研究,已经取得了很大的进展。这一新的研究课题的开展,是抗生素经典筛选的发展和扩大,也是开发微生物资源的新途径和新领域。它不仅为分子生物学、生物化学、免疫药理学等基础学科提供了有效的分析研究工具,并进一步推动了这些学科的发展;更有意义的是发现了一些引人注目的非抗菌性临床有效的微生物药物。本文仅就这一课题近年来的研究进展进行综述和讨论。
In the past two decades, great progress has been made in the systematic screening of small-molecule enzyme inhibitors from microbial secondary metabolites. The launching of this new research project is the development and expansion of the classic screening of antibiotics and is also a new way and new area for the development of microbial resources. It not only provides effective analytical and research tools for basic disciplines such as molecular biology, biochemistry and immunopharmacology, but also further promotes the development of these disciplines. What is even more significant is the discovery of some remarkable non-antibacterial clinically effective Microbial drugs. This article reviews and discusses the research progress of this topic in recent years.